Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Argus Health
Moodys
Express Scripts
Chubb
Covington
AstraZeneca
Cerilliant

Generated: May 27, 2018

DrugPatentWatch Database Preview

PALONOSETRON HYDROCHLORIDE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Palonosetron Hydrochloride patents expire, and when can generic versions of Palonosetron Hydrochloride launch?

Palonosetron Hydrochloride is a drug marketed by Dr Reddys Labs Ltd, Sandoz Inc, Teva Pharms Usa, Exela Pharma Science, and Fresenius Kabi Usa. and is included in six NDAs.

The generic ingredient in PALONOSETRON HYDROCHLORIDE is palonosetron hydrochloride. There are twenty-one drug master file entries for this compound. Eight suppliers are listed for this compound. There are four tentative approvals for this compound. Additional details are available on the palonosetron hydrochloride profile page.
Drug patent expirations by year for PALONOSETRON HYDROCHLORIDE
Pharmacology for PALONOSETRON HYDROCHLORIDE
Synonyms for PALONOSETRON HYDROCHLORIDE
(2R,3R,6R)-2-methyl-6-(phenylsulfanyl)-3,6-dihydro-2H-pyran-3-ol
(3aS)-2-((3S)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride
(3aS)-2-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one Hydrochloride
(3aS)-2-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one monohydrochloride
(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one--hydrogen chloride (1/1)
(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one hydrochloride
(3as)-2-[(s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1h-benz[de]isoquinoline hydrochloride
(3aS)-2,3,3a,4,5,6-Hexahydro-2-((3S)-3-quinuclidinyl)-1H-benz(de)isoquinolin-1-one monohydrochloride
(3S)-3-[(3aS)-1-oxo-3a,4,5,6-tetrahydro-1H-benzo[de]isoquinolin-2(3H)-yl]-1-azabicyclo[2.2.2]octan-1-ium chloride
(R,S)-Palonosetron HCl
(S,R)-Palonosetron HCl
(S,S)-Palonosetron Hydrochloride
(S)-2-((S)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride
1021481-16-2
135729-62-3
135729-76-9
1H-Benz(de)isoquinolin-1-one, 2-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, monohydrochloride, (3aS)-
1H-Benz[de]isoquinolin-1-one,3,3a,4,5,6-hexahydro-, (3aS)- hydrochloride
1H-Benz[de]isoquinolin-1-one,3,3a,4,5,6-hexahydro-, [S-(R*,R*)]-, hydrochloride
1J5X5HPB4C
23310D4I19
729P623
A806977
AB0105782
AC-1293
AC1OCF9K
ACN-040771
AK162860
AKOS015895112
AKOS026751493
Aloxi
API0003734
BC201360
C-20102
CAS-135729-62-3
CC-33456
CCG-101081
CCG-221268
CHEBI:85157
CHEMBL1720
CPD000469233
CS-0621
CTK8F0325
D05343
DSSTox_CID_26610
DSSTox_GSID_46610
DSSTox_RID_81765
DTXSID8046610
EN300-221649
FT-0600824
HY-A0021
I14-20251
KS-00000SN1
MFCD00939524
MLS001424202
MolPort-005-932-622
MolPort-016-638-380
NC00331
NCGC00166415-01
NCGC00166415-03
NSC-743769
NSC743769
OLDRWYVIKMSFFB-SSPJITILSA-N
Onicit
Onicita
P2051
Palonosetron (Hydrochloride)
PALONOSETRON HCl
Palonosetron hydrochloride (Aloxi)
Palonosetron hydrochloride (JAN/USAN)
Palonosetron hydrochloride [USAN:JAN]
Palonosetron hydrochloride, (3R)-
Palonosetron hydrochloride, >=98% (HPLC)
Palonosetron hydrochloride, United States Pharmacopeia (USP) Reference Standard
Palonosetronhydrochloride hydrochloride
Paloxi
RL01606
RS-25259-197
RTC-070923
s3050
SAM001246791
SCHEMBL182478
SMR000469233
ST51052757
TC-070923
Tox21_112421
Tox21_112421_1
UNII-1J5X5HPB4C
UNII-23310D4I19
W-5346

US Patents and Regulatory Information for PALONOSETRON HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd PALONOSETRON HYDROCHLORIDE palonosetron hydrochloride INJECTABLE;INTRAVENOUS 201533-001 Apr 21, 2016 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Ltd PALONOSETRON HYDROCHLORIDE palonosetron hydrochloride SOLUTION;INTRAVENOUS 203050-002 Mar 1, 2016 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Usa PALONOSETRON HYDROCHLORIDE palonosetron hydrochloride INJECTABLE;INTRAVENOUS 090713-002 Mar 23, 2018 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Exela Pharma Science PALONOSETRON HYDROCHLORIDE palonosetron hydrochloride SOLUTION;INTRAVENOUS 207963-001 Aug 22, 2016 RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
QuintilesIMS
Cipla
Fish and Richardson
Daiichi Sankyo
McKinsey
Argus Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.